Similar articles

• Efficacy vs effectiveness in prostate-specific antigen screening.

  Albertsen PC. Albertsen PC. J Natl Cancer Inst. 2010 Mar 3;102(5):288-9. doi: 10.1093/jnci/djq002. Epub 2010 Feb 8. J Natl Cancer Inst. 2010. PMID: 20142583 No abstract available.
• [The PSA test does not hold for screening. Good--but not good enough].

  Holmström B, Johansson M, Bratt O, Stattin P. Holmström B, et al. Lakartidningen. 2010 Feb 17-23;107(7):436, 438-9. Lakartidningen. 2010. PMID: 20384076 Review. Swedish. No abstract available.
• PSA screening: the bottom line.

  Elhilali MM. Elhilali MM. CMAJ. 2000 Mar 21;162(6):791-2. CMAJ. 2000. PMID: 10750466 Free PMC article. No abstract available.
• [Screening for prostate cancer--what does the evidence show?].

  Borre M, Iversen P. Borre M, et al. Ugeskr Laeger. 2007 May 14;169(20):1887-8. Ugeskr Laeger. 2007. PMID: 17553362 Review. Danish.
• Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?

  Rosser CJ, Parker A. Rosser CJ, et al. J Urol. 2005 Sep;174(3):1154-5; author reply 1155-6. doi: 10.1097/01.ju.0000169211.49050.8f. J Urol. 2005. PMID: 16094093 No abstract available.